Whalesbook
Revenue Growth vs. Profit Decline
Indegene Ltd's latest financial results reveal a significant gap between its expanding revenue and its shrinking profits. The company celebrated crossing key revenue milestones, but investors are now scrutinizing declining profit margins and the long-term impact of rising merger and acquisition (M&A) costs on sustained growth.
Record Revenue Amid Profit Pressure
Indegene's revenue soared to ₹1,003.4 crore in the fourth quarter of FY26, up 32.8% year-on-year. This milestone, the first time quarterly revenue has surpassed ₹1,000 crore, was driven by strong demand for its digital services in life sciences. Dollar revenue also grew 25.6% to $109.7 million. However, this top-line success was overshadowed by a 32.2% drop in net profit, which fell to ₹79.7 crore from ₹117.6 crore a year ago. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) rose 10.9% to ₹163.6 crore, but the EBITDA margin tightened significantly to 16.3% from 19.5% in the same period. The stock closed down 0.41% at ₹497.70 on April 29, 2026, signaling that investors are focusing more on profit stability than just revenue growth.
Margin Compression and Valuation Concerns
Indegene's Price-to-Earnings (P/E) ratio, typically between 27x and 31x, suggests investors expect strong, consistent profitability. The current 16.3% EBITDA margin is a notable drop from its historical average of 19%-20% over the past four years. Chief Financial Officer Suhas Prabhu cited one-time merger and acquisition costs, including a ₹20.3 crore loss in Q4, for this decline. The healthcare technology sector, a large market for IT spending, is increasingly focused on AI and efficiency. Competitors like IQVIA Holdings trade at a lower P/E of 24.8x. Indegene's higher P/E implies market expectations for growth and profit that the recent results may challenge. Acquisitions, including BioPharm and WARN & Co., have contributed to short-term margin pressures. Although full-year revenue growth for FY26 accelerated to 23.6%, the Q4 margin squeeze requires close attention as the company integrates new acquisitions.
Investor Concerns and Valuation Risks
The sharp 32.2% drop in net profit and the reduction of EBITDA margins from 19.5% to 16.3% highlight potential vulnerabilities. While the company points to one-time M&A costs, continued acquisitions could lead to recurring expenses that impact profitability. Indegene's P/E ratio, higher than many peers, suggests its valuation depends on consistent profit growth. However, the recent margin compression raises questions about its pricing power and cost management within the competitive sector. Despite a 'Buy' consensus from analysts with an average price target of ₹568.57, indicating expected upside, a broker downgrade signals potential risks. These risks could limit future gains if profit margins do not recover as quickly as expected.
Analyst Outlook and Growth Prospects
Analysts generally remain positive, with a consensus 'Buy' rating and an average 12-month price target of ₹568.57, suggesting over 15% potential upside. Some price targets go as high as ₹690, reflecting confidence in Indegene's long-term growth, especially its client base and GenAI initiatives. Management noted that 53 clients now generate over $1 million annually. The company is confident about building momentum in FY27, supported by a strong sales pipeline and efficient revenue generation per employee. Operational cash flow surged 47.3% year-on-year to ₹650.8 crore, demonstrating robust cash generation that backs dividend payouts. However, investors will closely monitor FY27 forecasts for revenue growth and profit margins to see how Indegene manages integration costs and achieves consistent profitability.